2021
Can the complete blood count be used as a reliable screening tool for obstructive sleep apnea?
Cummins E, Waseem R, Piyasena D, Wang CY, Suen C, Ryan C, Wong J, Kryger M, Chung F. Can the complete blood count be used as a reliable screening tool for obstructive sleep apnea? Sleep And Breathing 2021, 26: 613-620. PMID: 34185230, DOI: 10.1007/s11325-021-02383-3.Peer-Reviewed Original ResearchConceptsApnea-hypopnea indexComplete blood countMean SpO2Intermittent hypoxiaBlood countScreening toolObstructive sleep apneaMean oxygen saturationBody mass indexMethodsThis retrospective studyNormal clinical rangeObstructive sleep apnea screeningHome sleep studiesReliable screening toolSleep apnea screeningSevere OSAOSA severityRed blood cellsSurgical patientsIndependent predictorsMass indexSleep apneaAHI scoreRetrospective studySleep studies
2016
Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. Journal Of Clinical Sleep Medicine 2016, 12: 9-17. PMID: 26194728, PMCID: PMC4702197, DOI: 10.5664/jcsm.5382.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaOrexin receptor antagonistMean AHIRespiratory effectsSleep apneaMultiple dosesReceptor antagonistIntra-individual variabilityModerate obstructive sleep apneaEffects of suvorexantLowest effective doseSleep laboratory studiesTotal sleep timeMean SpO2Single doseRespiratory functionOxygen saturationPulse oximetryPlaceboPatientsSleep timeAHIDay 4Mean increaseSuvorexant
2015
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2015, 109: 416-426. PMID: 25661282, DOI: 10.1016/j.rmed.2014.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAzepinesCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedOrexin Receptor AntagonistsPulmonary Disease, Chronic ObstructiveRespirationSeverity of Illness IndexSleepSleep Aids, PharmaceuticalSpirometryTreatment OutcomeTriazolesUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseSleep breathing disordersOrexin receptor antagonistPulmonary diseaseBreathing disordersReceptor antagonistModerate chronic obstructive pulmonary diseaseDay 4Effects of suvorexantModerate airflow limitationRespiratory depressant effectsApnea-hypopnea indexMaximum daily doseClinical research unitTotal sleep timeTreatment of insomniaMean AHICOPD patientsAirflow limitationHypopnea indexDaily doseMean SpO2Spirometry criteriaHypnotic medications